Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Συντάκτης Τίτλος [ Τύπος] Έτος Φίλτρα: Συντάκτης is Athyros, Vasilios G [Clear All Filters]
Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?.
J Clin Hypertens (Greenwich). 20(3), 469-471.
(2018). PCI and stable coronary heart disease--COURAGE to change our minds?.
Curr Vasc Pharmacol. 5(3), 173-4.
(2007). Omega-3 fatty acids: how can they be used in secondary prevention?.
Curr Atheroscler Rep. 10(6), 510-7.
(2008). Off target effects of statins shape total mortality?.
J Drug Assess. 5(1), 4-5.
(2016). Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors..
Curr Pharm Des. 20(40), 6215-9.
(2014). Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block..
Curr Vasc Pharmacol.
(2019). Nonalcoholic fatty liver disease and statins..
Metabolism. 64(10), 1215-23.
(2015). Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations..
Angiology. 64(8), 572-5.
(2013). Multifactorial intervention for the prevention of vascular complications of type 2 diabetes..
Hellenic J Cardiol. 50(6), 445-8.
(2009). Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Tre.
J Clin Lipidol. 11(1), 306-307.
(2017). Metabolic syndrome in clinical practice..
Cardiol J. 21(2), 209.
(2014). Metabolic syndrome and non-cardiac vascular diseases: an update from human studies..
Curr Pharm Des. 20(31), 4944-52.
(2014). Metabolic syndrome and arterial stiffness: the past, the present and the future..
J Cardiovasc Med (Hagerstown). 14(10), 687-9.
(2013). Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas..
Endocr Relat Cancer. 15(3), 693-700.
(2008). Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease..
Dig Dis Sci. 57(4), 1109.
(2012). Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome..
Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
(2012). Management of statin-intolerant high-risk patients..
Curr Vasc Pharmacol. 8(5), 632-7.
(2010). Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?.
Metabolism. 121, 154796.
(2021). Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases..
J Crohns Colitis. 8(9), 936-44.
(2014). Lipoprotein a: where are we now?.
Curr Opin Cardiol. 24(4), 351-7.
(2009). Lipid-lowering agents and new onset diabetes mellitus..
Expert Opin Pharmacother. 11(12), 1965-70.
(2010). Lipid lowering agents and the endothelium: an update after 4 years..
Curr Vasc Pharmacol. 10(1), 33-41.
(2012). Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study..
Diabetes Care. 26(7), 1955-60.
(2003). The JUPITER trial results boost the evidence for the use of hsCRP as a treatment target and as part of the assessment of vascular risk: time for new guidelines?.
Hellenic J Cardiol. 50(2), 89-91.
(2009). JUPITER: major implications for vascular risk assessment..
Curr Med Res Opin. 25(1), 133-7.
(2009).